Aflac Incorporated (NYSE:AFL) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. decreased its position in Aflac Incorporated (NYSE:AFL - Free Report) by 70.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,366 shares of the financial services provider's stock after selling 163,745 shares during the period. Connor Clark & Lunn Investment Management Ltd.'s holdings in Aflac were worth $7,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new stake in shares of Aflac during the 4th quarter valued at about $163,409,000. Amundi grew its position in shares of Aflac by 81.1% during the 4th quarter. Amundi now owns 2,753,513 shares of the financial services provider's stock valued at $285,181,000 after acquiring an additional 1,232,683 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Aflac by 471.4% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 600,000 shares of the financial services provider's stock valued at $67,080,000 after acquiring an additional 495,000 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Aflac by 670.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 556,576 shares of the financial services provider's stock valued at $57,572,000 after acquiring an additional 484,378 shares during the period. Finally, World Investment Advisors LLC acquired a new stake in shares of Aflac during the 3rd quarter valued at about $42,290,000. Hedge funds and other institutional investors own 67.44% of the company's stock.

Remove Ads

Insider Activity at Aflac

In related news, Director Charles D. Lake II sold 29,802 shares of Aflac stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $107.29, for a total value of $3,197,456.58. Following the completion of the sale, the director now owns 49,962 shares in the company, valued at approximately $5,360,422.98. This trade represents a 37.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joseph L. Moskowitz sold 1,000 shares of Aflac stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the sale, the director now owns 25,393 shares of the company's stock, valued at $2,733,048.59. This trade represents a 3.79 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,546 shares of company stock worth $5,863,616. Insiders own 0.80% of the company's stock.

Aflac Trading Up 1.1 %

Shares of AFL stock traded up $1.13 during trading on Wednesday, hitting $108.49. 1,846,789 shares of the stock traded hands, compared to its average volume of 1,883,772. The firm has a market capitalization of $59.30 billion, a P/E ratio of 11.30, a price-to-earnings-growth ratio of 3.24 and a beta of 0.93. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.10 and a quick ratio of 0.08. The firm's fifty day moving average price is $105.60 and its 200-day moving average price is $107.65. Aflac Incorporated has a 52-week low of $79.31 and a 52-week high of $115.50.

Aflac (NYSE:AFL - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The financial services provider reported $1.56 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.07). Aflac had a net margin of 28.76% and a return on equity of 16.20%. As a group, research analysts forecast that Aflac Incorporated will post 6.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Piper Sandler decreased their price target on shares of Aflac from $122.00 to $118.00 and set an "overweight" rating on the stock in a research note on Friday, February 7th. Morgan Stanley raised their price target on shares of Aflac from $98.00 to $105.00 and gave the company an "equal weight" rating in a research note on Friday, February 28th. Barclays decreased their price target on shares of Aflac from $98.00 to $95.00 and set an "underweight" rating on the stock in a research note on Friday, February 7th. BMO Capital Markets assumed coverage on shares of Aflac in a research note on Thursday, January 23rd. They issued a "market perform" rating and a $111.00 price target on the stock. Finally, Wells Fargo & Company decreased their price target on shares of Aflac from $104.00 to $102.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $103.36.

Aflac Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.